Recurrence Following Resection of Intraductal Papillary Mucinous Neoplasms: A Systematic Review to Guide Surveillance

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Feb 10

PMID 38337524

Authors

Aneesa Salahuddin

Varna Thayaparan

Ahmad Hamad

Willi Tarver

Jordan M Cloyd

Alex C Kim

Robyn Gebhard

Timothy M Pawlik

Bradley N Reames

Aslam Ejaz

Affiliations

Soon will be listed here.

Abstract

Patients who undergo resection for non-invasive IPMN are at risk for long-term recurrence. Further evidence is needed to identify evidence-based surveillance strategies based on the risk of recurrence. We performed a systematic review of the current literature regarding recurrence patterns following resection of non-invasive IPMN to summarize evidence-based recommendations for surveillance. Among the 61 studies reviewed, a total of 8779 patients underwent resection for non-invasive IPMN. The pooled overall median follow-up time was 49.5 months (IQR: 38.5-57.7) and ranged between 14.1 months and 114 months. The overall median recurrence rate for patients with resected non-invasive IPMN was 8.8% (IQR: 5.0, 15.6) and ranged from 0% to 27.6%. Among the 33 studies reporting the time to recurrence, the overall median time to recurrence was 24 months (IQR: 17, 46). Existing literature on recurrence rates and post-resection surveillance strategies for patients with resected non-invasive IPMN varies greatly. Patients with resected non-invasive IPMN appear to be at risk for long-term recurrence and should undergo routine surveillance.

Citing Articles

[Pancreatic cystic neoplasms].

Brunner M, Grutzmann R Chirurgie (Heidelb). 2024; 95(11):939-952.

PMID: 39207476 DOI: 10.1007/s00104-024-02143-5.

Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms-A Review.

Balaban D, Coman L, Balaban M, Costache R, Jinga M Diagnostics (Basel). 2024; 14(10).

PMID: 38786354 PMC: 11119521. DOI: 10.3390/diagnostics14101056.

References

Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang J, Levy P, Ohtsuka T . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17(5):738-753. DOI: 10.1016/j.pan.2017.07.007. View

Kang M, Jang J, Lee K, Chang Y, Kwon W, Kim S . Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014; 260(2):356-63. DOI: 10.1097/SLA.0000000000000470. View

Hirono S, Kawai M, Okada K, Miyazawa M, Shimizu A, Kitahata Y . Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2016; 160(2):306-17. DOI: 10.1016/j.surg.2016.04.007. View

Li Y, Zhu Z, Peng L, Jin Z, Sun L, Song B . The pathological features and prognoses of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm after surgical resection: a single institution series. World J Surg Oncol. 2020; 18(1):287. PMC: 7643344. DOI: 10.1186/s12957-020-02063-8. View

Marsoner K, Haybaeck J, Csengeri D, Waha J, Schagerl J, Langeder R . Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience. BMC Cancer. 2016; 16(1):844. PMC: 5096332. DOI: 10.1186/s12885-016-2887-8. View

Nakamura M, Miyasaka Y, Sadakari Y, Date K, Ohtsuka T . Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?. Ann Gastroenterol Surg. 2018; 1(2):90-98. PMC: 5881340. DOI: 10.1002/ags3.12012. View

Dhar V, Merchant N, Patel S, Edwards M, Wima K, Imbus J . Does Surgical Margin Impact Recurrence in Noninvasive Intraductal Papillary Mucinous Neoplasms?: A Multi-institutional Study. Ann Surg. 2018; 268(3):469-478. PMC: 10182406. DOI: 10.1097/SLA.0000000000002923. View

Cuillerier E, Cellier C, Palazzo L, Deviere J, Wind P, Rickaert F . Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas. Am J Gastroenterol. 2000; 95(2):441-5. DOI: 10.1111/j.1572-0241.2000.01764.x. View

Marchegiani G, Mino-Kenudson M, Sahora K, Morales-Oyarvide V, Thayer S, Ferrone C . IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2014; 261(5):976-83. PMC: 5614498. DOI: 10.1097/SLA.0000000000000813. View

10.

Jang D, Ryu J, Chung K, Lee B, Park J, Lee S . Risk Factors for Progression or Malignancy in Main-Duct and Mixed-Type Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas. 2015; 45(7):1027-31. DOI: 10.1097/MPA.0000000000000592. View

11.

Yamaguchi J, Kaneoka Y, Maeda A, Takayama Y, Onoe S, Isogai M . Positive surgical margins in surgically treated unifocal and multifocal IPMN. Int J Surg. 2016; 28:51-5. DOI: 10.1016/j.ijsu.2016.02.065. View

12.

Distler M, Kersting S, Niedergethmann M, Aust D, Franz M, Ruckert F . Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2013; 258(2):324-30. DOI: 10.1097/SLA.0b013e318287ab73. View

13.

Marchegiani G, Mino-Kenudson M, Ferrone C, Morales-Oyarvide V, Warshaw A, Lillemoe K . Patterns of Recurrence After Resection of IPMN: Who, When, and How?. Ann Surg. 2015; 262(6):1108-14. DOI: 10.1097/SLA.0000000000001008. View

14.

Sugimachi K, Mano Y, Matsumoto Y, Nakanoko T, Uehara H, Nakashima Y . Neutrophil-to-lymphocyte Ratio as a Predictor of Malignancy of Intraductal Papillary Mucinous Neoplasms. Anticancer Res. 2021; 41(3):1663-1669. DOI: 10.21873/anticanres.14929. View

15.

Hirono S, Shimizu Y, Ohtsuka T, Kin T, Hara K, Kanno A . Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol. 2019; 55(1):86-99. DOI: 10.1007/s00535-019-01617-2. View

16.

Miyasaka Y, Ohtsuka T, Tamura K, Mori Y, Shindo K, Yamada D . Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm. Ann Surg. 2015; 263(6):1180-7. DOI: 10.1097/SLA.0000000000001368. View

17.

Schnelldorfer T, Sarr M, Nagorney D, Zhang L, Smyrk T, Qin R . Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008; 143(7):639-46. DOI: 10.1001/archsurg.143.7.639. View

18.

Niedergethmann M, Grutzmann R, Hildenbrand R, Dittert D, Aramin N, Franz M . Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg. 2008; 32(10):2253-60. DOI: 10.1007/s00268-008-9692-8. View

19.

White R, DAngelica M, Katabi N, Tang L, Klimstra D, Fong Y . Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg. 2007; 204(5):987-93. DOI: 10.1016/j.jamcollsurg.2006.12.040. View

20.

Amini N, Habib J, Blair A, Rezaee N, Kinny-Koster B, Cameron J . Invasive and Noninvasive Progression After Resection of Noninvasive Intraductal Papillary Mucinous Neoplasms. Ann Surg. 2020; 276(2):370-377. PMC: 9844542. DOI: 10.1097/SLA.0000000000004488. View